valproic acid has been researched along with Liver Failure in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Liver Failure: Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 7.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| "The influence of chronic hepatic failure on the disposition kinetics of valproate (VPA) excretion via a phase II reaction was examined in rats treated with carbon tetrachloride (1." | 7.74 | Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride. ( Ishizaki, J; Khemawoot, P; Maruyama, C; Miyamoto, K; Noda, H; Tsukada, H; Yokogawa, K, 2007) |
| " In 5 pediatric patients with severe myoclonic epilepsy and valproic acid-induced liver failure, we identified 1 novel and 4 previously described pathogenic mutations in the linker region of this enzyme." | 3.74 | Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase gamma. ( Baron, M; Bös, M; Chinnery, PF; Elger, CE; Kornblum, C; Kunz, WS; Sassen, R; Stewart, JD; Taylor, RW; Zsurka, G, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 3.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| "The influence of chronic hepatic failure on the disposition kinetics of valproate (VPA) excretion via a phase II reaction was examined in rats treated with carbon tetrachloride (1." | 3.74 | Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride. ( Ishizaki, J; Khemawoot, P; Maruyama, C; Miyamoto, K; Noda, H; Tsukada, H; Yokogawa, K, 2007) |
| "Valproic acid (VPA) is an effective antiepileptic drug that may induce progressive microvesicular steatosis." | 1.40 | Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases. ( de Almeida, IT; Duran, M; IJlst, L; Luís, PB; Ruiter, J; Silva, MF; Wanders, RJ, 2014) |
| "To review our clinical experience and determine if there are appropriate signs and symptoms to consider POLG sequencing prior to valproic acid (VPA) dosing in patients with seizures." | 1.36 | POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. ( Bao, X; Koenig, MK; Lee, IC; Naviaux, RK; Saneto, RP; Weng, SW; Wong, LJ, 2010) |
| "Valproic acid (VPA) is an antiepileptic drug (AED) commonly used for generalized and focal epilepsies." | 1.33 | Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. ( Borusiak, P; Boxtermann, W; Brückner, R; Buesing, D; Degen, I; Degenhardt, V; Fitzek, S; Gerstner, T; Haensch, CA; Hanusch, R; Hartmann, M; Häussermann, P; Hoppen, T; Jungck, A; Kasper, JM; Kluger, G; Knapp, R; Koenig, SA; Korenke, GC; Kuhn, H; Lindmayer, F; Longin, E; Müller-Deile, A; Oehring, R; Richard, HH; Samii, K; Seitz, R; Specht, U; Weber, Y; Weidner, B, 2006) |
| "The brother has suffered from CPEO since early childhood but has had so far no other symptoms of a mitochondrial disease." | 1.31 | Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. ( Brandner, S; Kleinle, S; Krähenbühl, S; Liechti, S; Straumann, D, 2000) |
| "Valproic acid is an effective antiseizure medication that is also used for other indications such as migraine prophylaxis." | 1.30 | Multiorgan system failure caused by valproic acid toxicity. ( Pinkston, R; Walker, LA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 12 (52.17) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Finsterer, J | 1 |
| Luís, PB | 1 |
| Ruiter, J | 1 |
| IJlst, L | 1 |
| de Almeida, IT | 1 |
| Duran, M | 1 |
| Wanders, RJ | 1 |
| Silva, MF | 1 |
| London, F | 1 |
| Hadhoum, N | 1 |
| Outteryck, O | 1 |
| Vermersch, P | 1 |
| Zéphir, H | 1 |
| Zsurka, G | 1 |
| Baron, M | 1 |
| Stewart, JD | 1 |
| Kornblum, C | 1 |
| Bös, M | 1 |
| Sassen, R | 1 |
| Taylor, RW | 1 |
| Elger, CE | 2 |
| Chinnery, PF | 1 |
| Kunz, WS | 1 |
| Neyns, B | 1 |
| Hoorens, A | 1 |
| Stupp, R | 1 |
| Saneto, RP | 1 |
| Lee, IC | 1 |
| Koenig, MK | 1 |
| Bao, X | 1 |
| Weng, SW | 1 |
| Naviaux, RK | 1 |
| Wong, LJ | 1 |
| Hakonen, AH | 1 |
| Isohanni, P | 1 |
| Rantamäki, M | 1 |
| Kälviäinen, R | 1 |
| Nordin, A | 1 |
| Uusimaa, J | 1 |
| Paetau, A | 1 |
| Udd, B | 1 |
| Pihko, H | 1 |
| Wartiovaara, A | 1 |
| Clarkson, A | 1 |
| Choonara, I | 1 |
| Huang, YL | 1 |
| Hong, HS | 1 |
| Wang, ZW | 1 |
| Kuo, TT | 1 |
| Kaplan, PW | 1 |
| Koenig, SA | 1 |
| Buesing, D | 1 |
| Longin, E | 1 |
| Oehring, R | 1 |
| Häussermann, P | 1 |
| Kluger, G | 1 |
| Lindmayer, F | 1 |
| Hanusch, R | 1 |
| Degen, I | 1 |
| Kuhn, H | 1 |
| Samii, K | 1 |
| Jungck, A | 1 |
| Brückner, R | 1 |
| Seitz, R | 1 |
| Boxtermann, W | 1 |
| Weber, Y | 1 |
| Knapp, R | 1 |
| Richard, HH | 1 |
| Weidner, B | 1 |
| Kasper, JM | 1 |
| Haensch, CA | 1 |
| Fitzek, S | 1 |
| Hartmann, M | 1 |
| Borusiak, P | 1 |
| Müller-Deile, A | 1 |
| Degenhardt, V | 1 |
| Korenke, GC | 1 |
| Hoppen, T | 1 |
| Specht, U | 1 |
| Gerstner, T | 1 |
| Khemawoot, P | 1 |
| Maruyama, C | 1 |
| Tsukada, H | 1 |
| Noda, H | 1 |
| Ishizaki, J | 1 |
| Yokogawa, K | 1 |
| Miyamoto, K | 1 |
| Ponchaut, S | 1 |
| Van Hoof, F | 1 |
| Veitch, K | 1 |
| Caparros-Lefebvre, D | 1 |
| Lecomte-Houcke, M | 1 |
| Pruvot, FR | 1 |
| Declerck, N | 1 |
| Paris, JC | 1 |
| Petit, H | 1 |
| Parra, J | 1 |
| Iriarte, J | 1 |
| Pierre-Louis, SJ | 1 |
| Njølstad, PR | 1 |
| Skjeldal, OH | 2 |
| Agsteribbe, E | 1 |
| Huckriede, A | 1 |
| Wannag, E | 1 |
| Søvik, O | 1 |
| Waaler, PE | 1 |
| Pinkston, R | 1 |
| Walker, LA | 1 |
| König, SA | 1 |
| Vassella, F | 1 |
| Schmidt, D | 1 |
| Bergmann, A | 1 |
| Boenigk, HE | 1 |
| Despland, PA | 1 |
| Genton, P | 1 |
| Krämer, G | 1 |
| Löscher, W | 1 |
| Mayer, T | 1 |
| Nau, H | 1 |
| Schneble, H | 1 |
| Siemes, H | 1 |
| Stefan, H | 1 |
| Wolf, P | 1 |
| Thomson, MA | 1 |
| Lynch, S | 1 |
| Strong, R | 1 |
| Shepherd, RW | 1 |
| Marsh, W | 1 |
| Rasmussen, M | 1 |
| Sanengen, T | 1 |
| Skullerud, K | 1 |
| Kvittingen, EA | 1 |
| Krähenbühl, S | 1 |
| Brandner, S | 1 |
| Kleinle, S | 1 |
| Liechti, S | 1 |
| Straumann, D | 1 |
| Barrueto, F | 1 |
| Hack, JB | 1 |
| Spahr, L | 1 |
| Negro, F | 1 |
| Rubbia-Brandt, L | 1 |
| Marinescu, O | 1 |
| Goodman, K | 1 |
| Jordan, M | 1 |
| Frossard, JL | 1 |
| Hadengue, A | 1 |
1 review available for valproic acid and Liver Failure
| Article | Year |
|---|---|
[Recommendations for blood studies and clinical monitoring in early detection of valproate-associated liver failure. Results of a consensus conferences 9 May - 11 May 1997 in Berlin].
Topics: Adolescent; Adult; Anticonvulsants; Blood Coagulation Tests; Chemical and Drug Induced Liver Injury; | 1998 |
22 other studies available for valproic acid and Liver Failure
| Article | Year |
|---|---|
Valproic acid for myoclonic epilepsy in POLG1 carriers can be fatal.
Topics: Acute Disease; Anticonvulsants; Child; Diffuse Cerebral Sclerosis of Schilder; DNA Polymerase gamma; | 2021 |
Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases.
Topics: Acyl Coenzyme A; Adenosine Triphosphate; DNA, Mitochondrial; Guanosine Triphosphate; Humans; Liver F | 2014 |
Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure.
Topics: Adolescent; Anticonvulsants; Diffuse Cerebral Sclerosis of Schilder; Diffusion Magnetic Resonance Im | 2017 |
Clonally expanded mitochondrial DNA mutations in epileptic individuals with mutated DNA polymerase gamma.
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Diffuse Cerebral Sclerosis of Schilder; | 2008 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diffuse Cerebral Sclerosis of Schilder; DNA Mu | 2010 |
[Mitochondrial recessive ataxia syndrome (MIRAS) and valproate toxicity].
Topics: Anticonvulsants; Ataxia; DNA, Mitochondrial; Genes, Recessive; Humans; Liver Failure; Mutation; Synd | 2010 |
Surveillance for fatal suspected adverse drug reactions in the UK.
Topics: Anesthetics; Anti-Bacterial Agents; Anticonvulsants; Antineoplastic Agents; Child; Drug-Related Side | 2002 |
Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis.
Topics: Anticonvulsants; Child, Preschool; Drug Hypersensitivity; Fatal Outcome; Female; Humans; Lichenoid E | 2003 |
Nonconvulsive status epilepticus.
Topics: Anticonvulsants; Electroencephalography; Humans; Liver Failure; MELAS Syndrome; Prognosis; Retrospec | 2003 |
Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Chil | 2006 |
Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Anticonvulsants; Area Under Curve; Aspartate Am | 2007 |
Valproate and cytochrome c oxidase deficiency.
Topics: Animals; Child, Preschool; Cytochrome-c Oxidase Deficiency; Female; Humans; Liver Failure; Mitochond | 1995 |
Unusual electronmicroscopic changes in valproate-associated liver failure.
Topics: Adult; Female; Humans; Liver; Liver Failure; Microscopy, Electron; Valproic Acid | 1993 |
Valproate toxicity.
Topics: Adolescent; Humans; Liver Failure; Male; Status Epilepticus; Valproic Acid | 1996 |
Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenases; Anticonvulsants; Cells, Cultured; Child; Epilepsy, | 1997 |
Multiorgan system failure caused by valproic acid toxicity.
Topics: Acute Kidney Injury; Anticonvulsants; Emergencies; Humans; Liver Failure; Male; Middle Aged; Migrain | 1997 |
Orthotopic liver transplantation with poor neurologic outcome in valproate-associated liver failure: a need for critical risk-benefit appraisal in the use of valproate.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Fatal Outcome; Female; Humans; Infant; Liver Fai | 2000 |
Evidence that Alpers-Huttenlocher syndrome could be a mitochondrial disease.
Topics: Cerebral Cortex; Child; Child, Preschool; Diffuse Cerebral Sclerosis of Schilder; Epilepsy, Absence; | 2000 |
Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure.
Topics: Adult; Anticonvulsants; Contraindications; DNA, Mitochondrial; Fatal Outcome; Female; Humans; Liver | 2000 |
Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
Topics: Adult; Anticonvulsants; Coma; Humans; Hyperammonemia; Liver; Liver Failure; Male; Valproic Acid | 2001 |
Acute valproate-associated microvesicular steatosis: could the [13C]methionine breath test be useful to assess liver mitochondrial function?
Topics: Adult; Antimanic Agents; Breath Tests; Drug Overdose; Female; Hepatocytes; Humans; Liver Failure; Me | 2001 |